FDA Guidance on CT Mgmt during COVID-19
Health Care, Pharma Industry, Strategic Planning
FDA issued this guidance to provide general considerations to assist sponsors in assuring the safety of trial participants, maintaining compliance with good clinical practice (GCP), and minimizing risks to trial integrity during the COVID-19 pandemic.
Related Education Resources.
All ResourcesCommercialization of Personalized Medicines
Topic: Pharma Industry
Report
Members
EAP 102: Part 2 of Introduction to EAP
Topics: Additional Concepts, Closeout, EAP, Execution, Forecasting / Planning, Project Management, Strategic Planning
Presentation
Members
The Use of Direct-to-Patient Methods in Decentralized Clinical Trials in Israel
Topic: Direct-to-Patient
White Paper
Free
